Vol. 2 No. 10 (2022)
Reimbursement Recommendations

Trastuzumab Deruxtecan (Enhertu)

Published October 17, 2022

Key Messages

  • CADTH recommends that Enhertu be reimbursed by public drug plans for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer if certain conditions are met.
  • Enhertu should only be covered to treat adult patients with HER2-positive breast cancer that is unresectable or metastatic (i.e., has spread beyond the initial tumour site) who have previously received trastuzumab and taxane for locally advanced or metastatic disease, or have tumours that progressed within 6 months of neoadjuvant or adjuvant therapy with trastuzumab and taxane. Patients must not have previously received an anti-HER2 antibody drug conjugate in the metastatic setting.
  • Enhertu should only be reimbursed if prescribed without any other anticancer drugs by a clinician with expertise in treating advanced breast cancer and the cost of Enhertu is reduced.